Return to:

Delivery Models

View 8 related solutions for PAREXEL® BioPharm Unit


PAREXEL® BioPharm Unit

Helping to simplify your drug development journey.

Emerging companies like yours are the genesis of innovation for the biopharmaceutical industry. Recent data indicates that 80 percent of ongoing development programs originated outside the top 25 pharmaceutical companies. That’s why PAREXEL launched its BioPharm Unit in 2012 – to deliver innovative solutions to help small to mid-sized companies expand their in-house expertise, support internal decision-making and position themselves among industry leaders.

Companies that partner with the PAREXEL BioPharm Unit benefit from:

  • A senior PAREXEL executive who provides clear direc­tion and assures that our work links with your objectives
  • A flexible relationship model that allows you to access specific expertise, resources and technology when you need it most
  • Global drug development, scientific and regulatory expertise to help optimize protocols and trial design and navigate regulatory authorities for approval
  • Commercialization strategies to help accelerate development options, substantiate value and vet evidence with payer networks early and throughout development
  • Offices across Europe, Asia and the Americas that provide access to sites and patient populations around the world
  • Accountability for delivery, quality and alignment of incentives in meeting your clinical development milestones
  • Access to venture capital or funding partners 

Delivering therapeutic expertise that drives success

The BioPharm Unit designs and conducts the most effective proof-of-concept trials to decrease risk, accelerate go/no go decisions, avoid costly clinical development failures and plan for future clinical development.

Within this broad expertise, PAREXEL has extensive clinical trial experience in oncology and hematology; central nervous system disorders; cardiovascular, metabolic and infectious diseases; and many other therapeutic areas. 

Designing the right model to accomplish your goals

At PAREXEL, we know that no two projects are ever the same. That’s why we work closely with every client to determine the very best model, and then tailor that model to meet the specific needs of each company. By creating a true sense of project ownership and collaboration, we act as your partners, where our success is only measured by yours. 

From delivering smarter solutions to anticipating your specific needs, we truly believe the people you choose to work with make all the difference. When you choose PAREXEL, you not only get 100% dedication to every project, every time, you also get a partner who is focused on the most important thing of all – your success.

Key Materials

Venturing Into a New Era of CNS Drug Development to Improve Success

by Larry Ereshefsky, Rebecca Evans, Rohit Sood, Doug Williamson, and Brett English.

The article identifies three strategies that apply multidisciplinary solutions earlier in the development process to reduce failures and accelerate CNS drug development. Click here to download.  

The Past, Present & Future of Cancer Immunotherapy: An Overview

by Denis Miller, M.D., Oliver Bohnsack, M.D., Ph.D., and Richard Jacobs, M.D.

In this article our PAREXEL experts outline key strategies to consider for accelerating the drug development process in this class of treatment. Click here to download. 

PAREXEL Creates Customized Biopharm Unit

Q&A with Ubavka DeNoble, M.D. about small and mid-size company needs

Read about PAREXEL's Ubavka DeNoble’s Q+A with Contract Pharma on small/mid-sized biopharm needs. Click here.  

Explore PAREXEL® BioPharm Unit
All Solutions
All Solutions
Clinical Research

View More...

Early Phase Services

More of What You Need for a Stronger Start in Phase I. Your journey from new molecule to new medicine starts with appropriate subjects, world class facilities, and more timely results. PAREXEL® provides comprehensive early phase testing services through our own hospital-based clinical units on three continents.

read more

Late-Stage Clinical Operations

More Tools to Simplify Your Journey Before and After Approval When it’s time to shift your development journey toward commercialization to gain first market access, PAREXEL® is the partner to help you do it…seamlessly, securely, and cost-effectively.

read more

Clinical Trial Supplies & Logistics

Clinical Trials Are Now More Complex, But Your Journey Shouldn’t Be You need to test your new medicine in key markets worldwide, but organizing consistent delivery of your trial-related supplies to multiple locations is complicated. PAREXEL® offers smart tools for managing your clinical trial logistics.

read more

Phase II-III Services

Improving Your Journey by Improving Every Step of Your Clinical Trials. During the part of your journey from Proof-of-Concept through regulatory submission, PAREXEL® Phase II-III specialists optimize every step of your clinical trials by every means possible.

read more

Regulatory Compliance Services

Our trusted experts, including renowned former regulators, know how to institute proactive compliance and have a strong track record of helping companies get out of regulatory crises. They are well versed in biopharmaceutical, medical device / diagnostic regulations and ICH guidance, and are focused on the success of your products and company.

read more

Integrated Product Development

Journeys, of course, have varied destinations. But whether you’re taking a new molecule to market, exploring how to differentiate a current product, or evaluating new geographic options, PAREXEL®’s Integrated Product Development team can shorten your product’s time to market and provide the strategic bandwidth and marketplace resources to help that product achieve more commercially.

read more

Market Access Consulting

In this post-blockbuster era, traditional opportunities for sustained growth throughout your products’ long-term journey are limited. Biologics, biomarkers, genomics, personalized medicine, and proteomics offer promising alternatives, but commercial dynamics of the biopharmaceutical industry are uncertain.

read more

Medical Communications

Successful commercialization is no longer just about gaining regulatory approval. It is about meeting the needs of a growing number of stakeholders, including physicians, patients, governments and payers. Success requires integrated pharmaceutical teamwork, including the right Medical Communications expertise where needed, to address the traditional silos of R&D, marketing and regulatory and focus on the same goals.

read more